Navigation Links
FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents
Date:9/8/2008

evaluation", says Dr. Kundakovic, FluoroPharma's President. "We look forward to expanding our discovery and development of molecular imaging pharmaceuticals for PET to meet the growing needs in neurology and oncology."

About FluoroPharma

FluoroPharma, Inc., a privately-held molecular imaging company headquartered in Boston MA, engages in the discovery, development and commercialization of proprietary diagnostic imaging products for the PET market. The company's initial focus is the advancement of three imaging agents -- CardioPET, BFPET, and VasoPET -- for the efficient detection and assessment of acute and chronic forms of coronary artery disease (CAD). Other products in development include agents for the diagnosis of certain types of cancer and for the diagnosis and treatment of Alzheimer's disease. For more information, please visit http://www.fluoropharma.com.

This release may contain forward-looking statements within the meaning of the federal securities laws. Such forward-looking statements reflect, among other things, management's current expectations, plans and strategies, and anticipated financial results, all of which are subject to known and unknown risks, uncertainties and factors that may cause our actual results to differ materially from those expressed or implied by these forward-looking statements. Many of these risks are beyond our ability to control or predict including the company's need for additional funds, the company's dependence on a limited number of imaging compounds, the early state of the products the company is developing, uncertainties relating to clinical trials and regulatory reviews, competition and dependence on collaborative partners, the company's ability to avoid infringement of the patent rights of others, and the company's ability to obtain adequate patent protection and to enforce these rights. Because of these risks, uncertainties and assumptions, y
'/>"/>

SOURCE FluoroPharma, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Society of Interventional Radiology Applauds Reports Uterine Fibroid Embolization Recommendations
2. Artelis and Selexis Report Record Antibody Production Levels in CHO Cells of Over 31 Grams Per Liter
3. Human Genome Sciences Reports Initial Results of Randomized Phase 2 Trial of HGS-ETR1 in Combination With Bortezomib in Advanced Multiple Myeloma
4. Previous Claims of siRNA Therapeutic Effects Called into Question by Report in Human Gene Therapy
5. Regado Biosciences Reports Clinical Results for REG1 Anticoagulation System at European Society of Cardiology Congress 2008
6. Algeta Reports Positive Headline Phase II Data on Pain Palliation With Alpharadin
7. Pharmasset Reports Financial Results for Quarter Ended June 30, 2008
8. Cardium Reports on Second Quarter 2008 Highlights and Financial Results
9. Nature Publication Reports on Key Role of Bile Acids in Glucose Metabolism and Insulin Signaling
10. Alexza Reports 2008 Second Quarter Financial Results and Updates Development of Product Candidates
11. Isolagen, Inc. Reports Positive Top-line Results from Pivotal Phase III Studies of Isolagen Therapy(TM) in Wrinkles: Studies Meet All Primary Efficacy Endpoints and are Statistically Significant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/26/2015)...  Tandem Diabetes Care®, Inc. (NASDAQ: TNDM ... t:slim® and t:flex™ Insulin Pumps, today announced the pricing ... its common stock at a price to the public ... from this offering are expected to be $56.3 million, ... offering expenses payable by Tandem. All of the shares ...
(Date:2/26/2015)... , Feb. 26, 2015  Mail-service and ... consumers, employers and government health plans $23.3 ... released by the Pharmaceutical Care Management Association (PCMA). ... drugs offers one of the easiest ways to ... Mark Merritt . "Policymakers should resist efforts ...
(Date:2/26/2015)... , Feb. 26, 2015  BD Life Sciences, a ... BDX ), a leading global medical ... focused on enabling high-resolution biology, today announced that ... for highly multiplexed cell isolation and single-cell gene ... BD,s powerful BD FACS™ single-cell sorting instrumentation and ...
Breaking Medicine Technology:Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 2Tandem Diabetes Care Announces Pricing of Underwritten Public Offering of Common Stock 3PCMA: Report Shows High-Tech Specialty and Mail-Service Pharmacies Will Reduce Costs for Texas Employers, Consumers and Public Programs by $23.3 Billion 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 2BD and Cellular Research Announce Co-marketing Efforts for Single-Cell Sequencing 3
... YORK, Dec. 15, 2011  New York University and the ... they have appointed Theodore (Ted) Rappaport, 51, to lead ... Rappaport, currently the William and Bettye ... at Austin (UTA), is a leading educator and entrepreneur ...
... 15, 2011  Today, the Consumer Healthcare Products Association (CHPA), announced ... Five Moms campaign to raise awareness of ... of two teenage boys and a high school math teacher ... the dangers of substance abuse. Millions of ...
Cached Medicine Technology:Wireless Engineering Pioneer Joins NYU-Poly and NYU 2Wireless Engineering Pioneer Joins NYU-Poly and NYU 3Wireless Engineering Pioneer Joins NYU-Poly and NYU 4CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 2CHPA's Five Moms Campaign to Stop Medicine Abuse Welcomes New Mom Tammy Walsh 3
(Date:2/27/2015)... February 27, 2015 Qualis Health, ... organizations, has been named a finalist in the ... recognition of outstanding commitment toward continuous improvement in ... in reducing hospital readmission rates through its Communities ... are honored to receive this national recognition, which ...
(Date:2/27/2015)... February 27, 2015 Jvion announced ... is collaborating with the Atlanta-based software company through ... of Jvion’s advanced predictive capabilities suite within the ... that identifies and prevents financial and clinical losses ... predictions that help prevent patient deterioration and suffering, ...
(Date:2/27/2015)... WI (PRWEB) February 27, 2015 UAS ... Adult Cubes, at Natural Products Expo West, March 6 ... are very excited to release the hands down best ... cream taste with an extra zing of Vitamin C. ... Cubes, winner of the NutrAward 2014, Delicious Living’s Supplement ...
(Date:2/27/2015)... (PRWEB) February 27, 2015 Aligned ... five local neighborhood health centers, officially welcomes Dr. ... Medicine based in Aligned Modern Health’s Lincoln Square, ... graduated from the National University of Health Sciences ... Award. She has completed post-graduate coursework in ...
(Date:2/27/2015)... 2015 The purpose of the Rouche ... to explore the current use of 3D printing in ... contribute to the Survey about 3D Printing please go ... use among large and small companies from a wide ... recent PwC and Manufacturing Institute survey of 3D Printing ...
Breaking Medicine News(10 mins):Health News:Qualis Health Named Award Finalist for Care Transitions Work 2Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 2Health News:Jvion Gains Strategic Collaboration Partner in Martin Ventures 3Health News:UAS LifeSciences to Launch UP4 Adult Cubes at Expo West 2Health News:Chicago Wellness Centers Welcomes New Lead Functional Medicine Doctor to Staff 2Health News:Chicago Wellness Centers Welcomes New Lead Functional Medicine Doctor to Staff 3Health News:Survey of Texas Manufacturers, Technology, Life Sciences and Innovation Companies Reveals Broad, Varied Interest and Skills Shortage in 3D Printing Applications Says NAU 2Health News:Survey of Texas Manufacturers, Technology, Life Sciences and Innovation Companies Reveals Broad, Varied Interest and Skills Shortage in 3D Printing Applications Says NAU 3
... procedures, survey shows , FRIDAY, July 31 (HealthDay News) -- ... visited a plastic surgeon for a "makeover" -- a ... around her lips and at the corners of her mouth. ... might lose her competitive edge in a tightening job market. ...
... , , WASHINGTON, July 31 ... Tobacco-Free Kids: , , (Logo: ... Council has taken an important step to protect the District,s kids and ... tax by 50 cents to $2.50 per pack - the seventh highest ...
... Fla., July 31 Sanofi-aventis US announced yesterday that the FDA ... in the USA. It offers results that last for years. Dr ... the product while abroad. It was approved in Europe(CE) for over ... global pharmaceutical company. The FDA approval is based on results from ...
... Md., July 31 /PRNewswire-Asia/ -- Chindex International, Inc.,("Chindex") (Nasdaq: ... products and services in the People,s Republic of China, today,announced ... results,on Monday, August 10, 2009, before the market opens. Management ... 10, 2009 to discuss financial results. , ...
... , , ... Administration (FDA) today approved the first and only antipsychotic for ... were approved for the acute treatment of schizoaffective disorder either ... INVEGA(R) was approved in 2006 for the treatment of schizophrenia. ...
... , Campaign Officially Launches ... months of college students and others wrestling with the creative challenge ... for its nationwide sign design contest. The victors are Kelsey Hazzard, ... law school this fall at the University of Virginia, and Christina ...
Cached Medicine News:Health News:Plastic Surgeons Stay Busy in Recession 2Health News:Plastic Surgeons Stay Busy in Recession 3Health News:District of Columbia Cigarette Tax Increase Delivers Victory for Kids and Taxpayers 2Health News:Chindex International, Inc. to Report First Quarter Fiscal 2010 Financial Results 2Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 2Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 3Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 4Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 5Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 6Health News:INVEGA(R) Approved as the First and Only Treatment for Schizoaffective Disorder 7Health News:CandleInTheWindow.org Announces $1000 Scholarship Prize Winners 2
... is a standard gelling temperature, high gel ... than 1,000 bp. This Genetic Technology Grade™ ... DNA electrophoresis. DNA recovered from SeaKem GTG ... ligated. SeaKem GTG Agarose is extensively performance ...
... is recommended for separations of DNA fragments ... that are easy to handle, and remains ... minimizes the risk of cracking or breaking. ... (GQT) products with similar sieving properties, is ...
The WADiana Compact is a fully automated immuno-haematology analyser, easy to use with maximum security including clot detection and ensuring no contamination....
... PK7200 works on patented microplate agglutination ... testing system for donor ABO/Rh testing. PK7200 ... syphilis and cytomegalovirus antibody detection. The Automated ... along with the proven reliability that for ...
Medicine Products: